Literature DB >> 1285215

Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer.

A M Kluftinger1, B W Robinson, N F Quenville, R J Finley, N L Davis.   

Abstract

Both epidermal growth factor receptor (EGFr) and the oncogene product of c-erbB2 have been shown to be expressed by human malignancies, and in some cases to relate to clinical outcomes. This study investigates the correlation between the presence of these receptor proteins and known prognostic indicators of colorectal cancer. Indirect immunoperoxidase staining of 32 freshly frozen surgical specimens revealed an overall expression of EGFr and c-erbB2 of 43% and 38%, respectively. A significantly higher rate of EGFr expression was found in tumours of more advanced stage (Dukes C and D), poor differentiation and those exhibiting vascular and lymphatic invasion. The presence of the c-erbB2 protein did not correlate with any of these variables. Expression of these molecules appeared to be independent and positive staining for both receptors occurred in only 19% of cases. EGFr may play a future role as a prognostic tool in colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1285215     DOI: 10.1016/0960-7404(92)90062-p

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  22 in total

1.  FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk.

Authors:  Alexandros Garouniatis; Adamantia Zizi-Sermpetzoglou; Spyros Rizos; Alkiviadis Kostakis; Nikolaos Nikiteas; Athanasios G Papavassiliou
Journal:  Int J Colorectal Dis       Date:  2012-06-26       Impact factor: 2.571

2.  Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer.

Authors:  Alenka Ličar; Petra Cerkovnik; Srdjan Novaković
Journal:  Med Oncol       Date:  2010-07-20       Impact factor: 3.064

Review 3.  KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

Authors:  J H J M van Krieken; A Jung; T Kirchner; F Carneiro; R Seruca; F T Bosman; P Quirke; J F Fléjou; T Plato Hansen; G de Hertogh; P Jares; C Langner; G Hoefler; M Ligtenberg; D Tiniakos; S Tejpar; G Bevilacqua; A Ensari
Journal:  Virchows Arch       Date:  2008-09-18       Impact factor: 4.064

4.  Clinical significance of KRAS gene mutation and epidermal growth factor receptor expression in Japanese patients with squamous cell carcinoma of the larynx, oropharynx and hypopharynx.

Authors:  Satoshi Fujii; Hideoki Uryu; Ken Akashi; Kensuke Suzuki; Manabu Yamazaki; Makoto Tahara; Ryuichi Hayashi; Atsushi Ochiai
Journal:  Int J Clin Oncol       Date:  2012-03-24       Impact factor: 3.402

Review 5.  A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.

Authors:  Vanessa Deschoolmeester; Marc Baay; Pol Specenier; Filip Lardon; Jan B Vermorken
Journal:  Oncologist       Date:  2010-06-28

6.  β-catenin and Her2/neu expression in rectal cancer: association with histomorphological response to neoadjuvant therapy and prognosis.

Authors:  Uta Drebber; Martin Madeja; Margarete Odenthal; Inga Wedemeyer; Stefan P Mönig; Jan Brabender; Elfriede Bollschweiler; Arnulf H Hölscher; Paul M Schneider; Hans P Dienes; Daniel Vallböhmer
Journal:  Int J Colorectal Dis       Date:  2011-05-03       Impact factor: 2.571

7.  Modification of the primary tumor microenvironment by transforming growth factor alpha-epidermal growth factor receptor signaling promotes metastasis in an orthotopic colon cancer model.

Authors:  Takamitsu Sasaki; Toru Nakamura; Robert B Rebhun; Hua Cheng; Katherine Stemke Hale; Rachel Z Tsan; Isaiah J Fidler; Robert R Langley
Journal:  Am J Pathol       Date:  2008-07       Impact factor: 4.307

8.  ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery.

Authors:  Glauco Baiocchi; Ademar Lopes; Renata A Coudry; Benedito M Rossi; Fernando A Soares; Samuel Aguiar; Gustavo C Guimarães; Fabio O Ferreira; Wilson T Nakagawa
Journal:  Int J Colorectal Dis       Date:  2009-04-24       Impact factor: 2.571

9.  The neu oncogene product in serum and tissue of patients with metastatic gastrointestinal carcinomas.

Authors:  W Vogel; R Kath; H Kosmehl; E Olschowsky; K Höffken
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

10.  Higher LNM rate and poorer prognosis of early-onset compared to late-onset T1 stage colorectal cancer: a large-population based study.

Authors:  Chao-Tao Tang; Zi-Xiang Guo; Peng Wang; You-Xiang Chen; Chun-Yan Zeng
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.